PDF icon Download PDF
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2021; 10(02): 107-111
DOI: 10.1055/s-0041-1731576
Original Article: Gynaecological Cancer

CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers

Tejinder Kataria
1   Division of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
,
Pushpa Naga
1   Division of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
,
Susovan Banerjee 
1   Division of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
,
Deepak Gupta
1   Division of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
,
Kushal Narang
1   Division of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
,
Manoj Tayal
1   Division of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
,
Shyam Singh Bisht
1   Division of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
› Author Affiliations
Funding None.
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Abstract

Purpose Use of stereotactic ablative radiotherapy (SABR) in the treatment of recurrent or metastatic lesions from a primary gynecologic cancer is a relatively new concept. The present study aims to assess the safety, efficacy, and possible toxicity profile of CyberKnife SABR, recurrent or metastatic disease.

Materials/Methods CyberKnife VSI-based SABR was offered to 20 oligometastatic/recurrent gynecological cancer patients between 2013 and 2019. Patient, tumor, and treatment characteristics including radiotherapy details, clinical outcome in terms of local control rates, and toxicities are reported in this study.

Results Twenty-five recurrent or oligometastatic lesions for 20 primary gynecologic cancer patients including cervical (n = 8), ovarian (n = 6), endometrial (n = 5), and vulvar (n = 1) cancers were analyzed. Of these, 4 (16%) were intracranial lesions and remaining 21 (84%) were extracranial, consisting of 14 (67%) extrapelvic and 7 (33%) pelvic lesions. The median SABR dose delivered was 60 Gy biologically effective dose (range 42–133 Gy) in an average of four fractions (range 1–6). The mean follow-up was 18 (range 2–70) months. Local tumor control was achieved in 82% of patients. There was no grade ≥ 3 toxicity recorded.

Conclusion Our study results suggest that CyberKnife SABR is an effective treatment modality with no major morbidity in patients with recurrent or oligometastatic gynecological cancers.

Keywords

gynecological cancer - recurrent - oligometastasis - stereotactic body radiation therapy - CyberKnife - survivals


Publication History

Article published online:
04 July 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India